中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共3条，第1-3条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation 期刊论文
ONCOTARGET, 2016, 卷号: 7, 期号: 43, 页码: 69760-69769
作者:  Wang, Aoli;  Yan, Xiao-E;  Wu, Hong;  Wang, Wenchao;  Hu, Chen;  Chen, Cheng;  Zhao, Zheng;  Zhao, Peng;  Li, Xixiang;  Wang, Li;  Wang, Beilei;  Ye, Zi;  Wang, Jinhua;  Wang, Chu;  Zhang, Wei;  Gray, Nathanael S.;  Weisberg, Ellen L.;  Chen, Liang;  Liu, Jing;  Yun, Cai-Hong;  Liu, Qingsong
浏览  |  Adobe PDF(2026Kb)  |  收藏  |  浏览/下载：115/59  |  提交时间：2017/11/21
Ibrutinib  Egfr Kinase  Dfg-in/c-helix-out  Inactive Conformation  Nsclc  
Simultaneous inhibition of Vps34 kinase would enhance PI3K delta inhibitor cytotoxicity in the B-cell malignancies 期刊论文
ONCOTARGET, 2016, 卷号: 7, 期号: 33, 页码: 53515-53525
作者:  Liu, Xiaochuan;  Wang, Aoli;  Liang, Xiaofei;  Liu, Juanjuan;  Zou, Fengming;  Chen, Cheng;  Zhao, Zheng;  Deng, Yuanxin;  Wu, Hong;  Qi, Ziping;  Wang, Beilei;  Wang, Li;  Liu, Feiyang;  Xu, Yunhe;  Wang, Wenchao;  Fernandes, Stacey M.;  Stone, Richard M.;  Galinsky, Ilene A.;  Brown, Jennifer R.;  Loh, Teckpeng;  Griffin, James. D.;  Zhang, Shanchun;  Weisberg, Ellen L.;  Zhang, Xin;  Liu, Jing;  Liu, Qingsong
浏览  |  Adobe PDF(7625Kb)  |  收藏  |  浏览/下载：89/37  |  提交时间：2017/11/21
Pi3k Delta  Vps34  Combination  Chronic Lymphatic Leukemia  Acute Myeloid Leukemia  
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML) 期刊论文
ONCOTARGET, 2016, 卷号: 7, 期号: 29, 页码: 45562-45574
作者:  Liu, Feiyang;  Wang, Beilei;  Wang, Qiang;  Qi, Ziping;  Chen, Cheng;  Kong, Lu-Lu;  Chen, Ji-Yun;  Liu, Xiaochuan;  Wang, Aoli;  Hu, Chen;  Wang, Wenchao;  Wang, Huiping;  Wu, Fan;  Ruan, Yanjie;  Qi, Shuang;  Liu, Juan;  Zou, Fengming;  Hu, Zhenquan;  Wang, Wei;  Wang, Li;  Zhang, Shanchun;  Yun, Cai-Hong;  Zhai, Zhimin;  Liu, Jing;  Liu, Qingsong
浏览  |  Adobe PDF(8054Kb)  |  收藏  |  浏览/下载：244/195  |  提交时间：2017/11/21
Bcr-abl  Pdgfr  Chronic Myeloid Leukemia  Kinase Inhibitor